CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for LogicBio Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

LogicBio Therapeutics, Inc.
65 Hayden Ave, 2Nd Floor
Phone: (617) 245-0399p:617 245-0399 LEXINGTON, MA  02421  United States Fax: (302) 655-5049f:302 655-5049

This company was Merged or Acquired on 11/16/2022.
This company ceased filing statements with the SEC on 11/29/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
LogicBio Therapeutics, Inc. is a clinical-stage genetic medicine company. It is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001 is developed for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. It is developing LB-401 for the treatment of hereditary tyrosinemia type 1. It is also developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202212/31/2021YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer & Director FredericChereau
Independent Chairman of the Board Richard A.Moscicki 70 6/1/2020 10/1/2018
Chief Operating Officer SandraPoole
20 additional Officers and Directors records available in full report.

Business Names
Business Name
LOGC
LOGICBIO AUSTRALIA PTY LIMITED
LOGICBIO SECURITIES CORPORATION

General Information
Number of Employees: 62 (As of 12/31/2021)
Outstanding Shares: 32,962,733 (As of 11/8/2022)
Shareholders: 14
Stock Exchange: NASD
Federal Tax Id: 471514975
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024